JP2016515623A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515623A5
JP2016515623A5 JP2016506607A JP2016506607A JP2016515623A5 JP 2016515623 A5 JP2016515623 A5 JP 2016515623A5 JP 2016506607 A JP2016506607 A JP 2016506607A JP 2016506607 A JP2016506607 A JP 2016506607A JP 2016515623 A5 JP2016515623 A5 JP 2016515623A5
Authority
JP
Japan
Prior art keywords
liquid pharmaceutical
pharmaceutical formulation
furosemide
aminomethane
hydroxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016506607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515623A (ja
JP6415535B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/032800 external-priority patent/WO2014165660A1/en
Publication of JP2016515623A publication Critical patent/JP2016515623A/ja
Publication of JP2016515623A5 publication Critical patent/JP2016515623A5/ja
Application granted granted Critical
Publication of JP6415535B2 publication Critical patent/JP6415535B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016506607A 2013-04-05 2014-04-03 フロセミドの皮下投与用の医薬製剤 Active JP6415535B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808962P 2013-04-05 2013-04-05
US61/808,962 2013-04-05
PCT/US2014/032800 WO2014165660A1 (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018187299A Division JP6677779B2 (ja) 2013-04-05 2018-10-02 フロセミドの皮下投与用の医薬製剤

Publications (3)

Publication Number Publication Date
JP2016515623A JP2016515623A (ja) 2016-05-30
JP2016515623A5 true JP2016515623A5 (enExample) 2017-05-18
JP6415535B2 JP6415535B2 (ja) 2018-10-31

Family

ID=51659206

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016506607A Active JP6415535B2 (ja) 2013-04-05 2014-04-03 フロセミドの皮下投与用の医薬製剤
JP2018187299A Active JP6677779B2 (ja) 2013-04-05 2018-10-02 フロセミドの皮下投与用の医薬製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018187299A Active JP6677779B2 (ja) 2013-04-05 2018-10-02 フロセミドの皮下投与用の医薬製剤

Country Status (14)

Country Link
US (5) US9884039B2 (enExample)
EP (2) EP3799869B1 (enExample)
JP (2) JP6415535B2 (enExample)
KR (2) KR102493735B1 (enExample)
CN (1) CN105431145B (enExample)
AU (1) AU2014248164B2 (enExample)
CA (1) CA2908935C (enExample)
DK (1) DK2981258T3 (enExample)
ES (1) ES2823589T3 (enExample)
IL (1) IL241917B (enExample)
MX (1) MX367165B (enExample)
PT (1) PT2981258T (enExample)
SG (2) SG11201508251RA (enExample)
WO (1) WO2014165660A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367165B (es) * 2013-04-05 2019-08-07 Scpharmaceuticals Inc Formulaciones farmacéuticas para administración subcutánea de furosemida.
DE102014115951A1 (de) 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
US12403120B2 (en) * 2018-12-10 2025-09-02 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
IL300152A (en) 2020-08-05 2023-03-01 Scpharmaceuticals Inc Methods of treatment using furosemide
WO2022212813A1 (en) 2021-04-02 2022-10-06 Scpharmaceuticals Inc. Subcutaneous infusion of furosemide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663348A (en) 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) * 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
JP3267613B2 (ja) * 1991-05-30 2002-03-18 アボツト・ラボラトリーズ イオン捕獲結合アッセイにおける非特異的結合遮断薬を含む試薬
US5633240A (en) * 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
IT1283608B1 (it) * 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
ATE409280T1 (de) 2005-12-28 2008-10-15 Sensile Pat Ag Mikropumpe
CA2658394C (en) 2006-07-12 2016-08-16 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US7923447B2 (en) * 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
CA2735660C (en) * 2008-09-09 2017-05-30 Cima Labs Inc. Dosage forms for weakly ionizable compounds
EP2473226A1 (en) * 2009-09-04 2012-07-11 Minipumps LLC Adhesive skin patch with pump for subcutaneous drug delivery
AU2012325801B2 (en) 2011-10-19 2016-05-12 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
MX367165B (es) 2013-04-05 2019-08-07 Scpharmaceuticals Inc Formulaciones farmacéuticas para administración subcutánea de furosemida.

Similar Documents

Publication Publication Date Title
JP2016515623A5 (enExample)
JP2016539921A5 (enExample)
JP2016034978A5 (enExample)
FI3310809T3 (fi) Anti-cgrp-vasta-aineformulaatio
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
FI3685847T3 (fi) Komplementtiaktiivisuuden modulaattoreita
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
RU2017134443A (ru) Способ лечения с применением традипитанта
PE20190405A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4beta7
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
JP2016512564A5 (enExample)
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
JP2016027060A5 (enExample)
JP2017014206A5 (enExample)
JP2018172440A5 (enExample)
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
FI3383385T4 (fi) Melflufeeniannoskuureja syöpään
RU2016112257A (ru) Композиция для лечения гипертензии и/или фиброза
HRP20181021T1 (hr) Formulacija za bispecifične aktivatore limfocita t (bites)
EA201792144A1 (ru) Стабильный препарат для парентерального введения тапентадола